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Introduction
The AMP-activated protein kinase (AMPK) has been pro-
posed to act as a fuel sensor capable of mediating the cel-
lular adaptation to nutritional and environmental vari-
ations (1). AMPK is a ubiquitous serine/threonine
protein kinase activated in response to environmental or
nutritional stress factors that deplete intracellular ATP
levels. AMPK is a heterotrimeric enzyme consisting of an
α catalytic subunit and noncatalytic regulatory β and γ
subunits. Two isoforms have been identified for both the
α subunit (α1 and α2) and β subunit (β1 and β2), and
three isoforms have been reported for the γ subunit (γ1,
γ2, and γ3). Regulation of AMPK activity is complex,
involving allosteric activation by AMP and covalent
modification by phosphorylation via an upstream
AMPK kinase (2). Phosphorylation of threonine 172 in
the α subunit of AMPK is essential for its activation (2).
Metabolic actions of AMPK have been extensively
studied in skeletal muscle. Activation of AMPK by 
5-aminoimidazole-4-carboxamide-1-β-D-ribofura-
noside (AICAR) has been demonstrated to increase
muscle glucose uptake in vivo and in vitro via an acute
insulin-independent mechanism (3, 4) and to decrease
the glycogen synthase activity ratio (5). Implication of
AMPK in the physiology of tissues other than skeletal
muscle has also been suggested by findings in liver
(6–8), pancreas (9, 10), and adipose tissue (4, 7, 11, 12).
Lastly, AMPK is also expressed in the CNS (13), but the
role of AMPK in this tissue remains to be determined.
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AMP-activated protein kinase (AMPK) is viewed as a fuel sensor for glucose and lipid metabolism.
To better understand the physiological role of AMPK, we generated a knockout mouse model in
which the AMPKα2 catalytic subunit gene was inactivated. AMPKα2–/– mice presented high glucose
levels in the fed period and during an oral glucose challenge associated with low insulin plasma lev-
els. However, in isolated AMPKα2–/– pancreatic islets, glucose- and L-arginine–stimulated insulin
secretion were not affected. AMPKα2–/– mice have reduced insulin-stimulated whole-body glucose
utilization and muscle glycogen synthesis rates assessed in vivo by the hyperinsulinemic euglycemic
clamp technique. Surprisingly, both parameters were not altered in mice expressing a dominant-neg-
ative mutant of AMPK in skeletal muscle. Furthermore, glucose transport was normal in incubated
isolated AMPKα2–/– muscles. These data indicate that AMPKα2 in tissues other than skeletal mus-
cles regulates insulin action. Concordantly, we found an increased daily urinary catecholamine excre-
tion in AMPKα2–/– mice, suggesting altered function of the autonomic nervous system that could
explain both the impaired insulin secretion and insulin sensitivity observed in vivo. Therefore, extra-
muscular AMPKα2 catalytic subunit is important for whole-body insulin action in vivo, probably
through modulation of sympathetic nervous activity.
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In skeletal muscle, the actions of AMPK are thought
to be mediated mainly through the AMPKα2 isoform
(5, 14, 15). In other tissues, the physiological role of this
isoform in vivo is less clear. To get more insights into
this issue, we knocked out the AMPKα2 gene. In the
present study, we show that AMPKα2–/– mice exhibit
glucose intolerance that is associated with low plasma
insulin levels and reduced muscle glycogen synthesis
during hyperinsulinemic clamp conditions. Reduction
of insulin sensitivity was not dependent on muscle
AMPK activity, since mice expressing a dominant-neg-
ative mutant of AMPK in skeletal muscle are not
insulin resistant. Finally, AMPKα2–/– mice have
increased catecholamine urinary excretion, suggesting
increased sympathetic tone. Consequently, our data
suggest that the α2 catalytic subunit of AMPK plays a
major role in vivo as a fuel metabolic sensor by modu-
lating the activity of the autonomous nervous system.
Methods
Gene targeting and generation of AMPKα2 gene knockout
mice. AMPKα2 genomic clones were isolated after
screening a mouse 129 strain genomic library (Strata-
gene, Loyola, California, USA). The targeting construct
was generated by flanking exon C, which encodes the
AMPKα2 catalytic domain (corresponding to amino
acids 189–260), with loxP sites for the Cre recombinase
and inserting a PGK promoter–driven neomycin selec-
tion cassette flanked by an additional loxP site. The tar-
geting construct was linearized and electroporated into
129/Sv MPI-I embryonic stem cells. Targeted clones
were identified by Southern blot analysis of HindIII-
digested DNA using a flanking 5′ DNA fragment as a
hybridization probe and PCR analysis. Cells expanded
from targeted clones were injected into C57BL6 blas-
tocysts, and germline-transmitting chimeric animals
were mated with C57BL/6 mice. The resulting het-
erozygous offspring were bred with “deleter” EIIa-Cre
transgenic mice, in which Cre is expressed in the germ
cells, to produce AMPKα2+/– mice (16). These mice were
crossed to generate control and mutant mice. South-
ern blot analysis of HindIII-digested DNA with an
internal probe (Figure 1a) and PCR analysis were used
to genotype mice.
Animals. Control, AMPKα2–/–, and kinase-dead
AMPKα2 transgenic (Tg-KD-AMPKα2) male mice were
studied at 12 weeks of age. The establishment and char-
acterization of Tg-KD-AMPKα2 mice were previously
reported (17). Animals were housed under controlled
temperature (21°C) and lighting, with 12 hours of light
(7:00 am to 7:00 pm) and 12 hours of dark (7:00 pm to
7:00 am), and had free access to water and a standard
mouse chow diet. All procedures were performed in
accordance with the principles and guidelines estab-
lished by the European Convention for the Protection
of Laboratory Animals.
Body weight, food intake, and body composition. Mice were
weighed weekly after 3 weeks of age. Food intake was
measured daily for a period of 3 days using metabolic
cages (Marty Technologie, Paris, France) that allow free
access to tap water and food. Body composition analy-
sis was performed on anesthetized living mice by a
dual-energy x-ray absorptiometry method using a small
animal densitometer (PIXImus Lunar; GE Medical Sys-
tems, Madison, Wisconsin, USA). Careful dissection
and weighing of individual organs was also performed.
Tissue triglycerides were extracted with acetone, and
triglyceride content was measured with a commercial
kit (Sigma-Aldrich, St. Louis, Missouri, USA).
Blood and urinary parameters. Blood was withdrawn
from the tail using EDTA-aprotinin as the anticoagu-
lant. In the fed state, blood was collected at 9:00 pm.
For fasting experiments, food was removed at 5:00 pm,
and the mice were kept in a clean new cage for 5 hours
before blood collection. During the oral glucose toler-
ance test (OGTT) and AICAR tolerance test, blood glu-
cose levels were assessed using a glucometer (Glu-
cotrend II; Roche Diagnostics, Meylan, France). Serum
insulin concentrations were assessed using a rat insulin
ELISA kit with a mouse insulin standard (Crystal
Chem Inc., Chicago, Illinois, USA). Serum leptin con-
centrations were assessed with a mouse leptin ELISA
kit (Crystal Chem Inc.). Serum concentrations of potas-
sium, sodium, triglycerides, FFAs, glycerol, total and
HDL cholesterol, creatinine, and urea were determined
using an automated Monarch device (Instrumentation
Laboratory Co., Lexington, Massachusetts, USA). For
determination of urinary levels of catecholamines, ani-
mals were housed in individual metabolic cages, and
daily urinary catecholamine excretion during 3 con-
secutive days was determined by reverse-phase HPLC
(performed at Cochin Hospital, Paris, France).
Glucose and AICAR tolerance tests. During OGTT and
AICAR tolerance testing, blood was collected from the
tail vein at 0, 20, 40, 60, 80, 100, and 120 minutes for
determination of glucose levels. OGTTs were per-
formed in the morning after an overnight fast by oral
administration of 3 g glucose per kg body weight.
Blood was also collected at time 20 minutes in chilled
heparinized tubes for determination of plasma insulin
levels. To study the effect of α-adrenergic antagonist on
glucose tolerance, mice were injected intraperitoneally
with 10 mg/kg phentolamine 30 minutes before glu-
cose challenge. To study the effect of β-adrenergic
antagonist on glucose tolerance, mice were injected
intraperitoneally with 10 mg/kg propranolol 30 min-
utes before glucose challenge. AICAR tolerance tests
were performed in the morning by intraperitoneal
injection of 0.25 g AICAR per kg body weight into
overnight-fasted mice (17).
Hyperinsulinemic euglycemic clamp procedures. To deter-
mine the rate of glucose utilization, an indwelling
catheter was inserted into the femoral vein under anes-
thesia, sealed under the back skin, and glued on top of
the skull (18). The mice were then housed individually.
After 2 days, they showed normal feeding behavior and
motor activity. The mice were allowed to recover for 4–6
days. On the day of the experiment, the mice were fast-
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ed for 6 hours. The whole-body glucose utilization rate
was determined under basal and hyperinsulinemic eug-
lycemic conditions. In the basal state, HPLC-purified 
D-(3-3H)-glucose (NEN Life Science Products Inc.,
Boston, Massachusetts, USA) was continuously infused
through the femoral vein at a rate of 10 µCi/kg.min for
3 hours. In the hyperinsulinemic condition, insulin was
infused at a rate of 6 mU/kg.min for 3 hours; D-(3-3H)-
glucose was infused at rate of 30 µCi/kg.min — a higher
rate than for the basal condition, to ensure a detectable
plasma D-(3-3H)-glucose enrichment. Throughout the
infusion, blood glucose was assessed from blood sam-
ples and euglycemia was maintained by periodically
adjusting a variable infusion of 16.5% (wt/vol) glucose.
Plasma glucose concentrations, D-(3-3H)-glucose specif-
ic activity, and 3H2O and D-(3-3H)-glucose enrichments
were determined as previously described (18). Glucose
turnover and whole-body glycolysis rate were calculated
as described (18). Whole-body glycogen synthesis was
calculated by subtracting the whole-body glycolytic rate
from the glucose turnover rate. The mean was calculat-
ed for each timepoint for this period. The mean value of
mice from the same group was reported. Mice showing
variations in specific activity larger than 15% were
excluded from the study.
Determination of total glycogen content and glycogen syn-
thesis rate in skeletal muscle and liver. At completion of the
infusion, the hind limb and the main lobe of the liver
were removed and ground into liquid nitrogen for
determination of total glycogen content and glycogen
synthesis rate. Total glycogen was extracted from 20 mg
of liver or 100 mg of muscle by digesting tissue samples
in KOH. An aliquot was neutralized with HCl and the
glycogen content was assessed
using amyloglucosidase (19). Mus-
cle glycogen synthesis rate was
determined by extracting glycogen
with perchloric acid (6% wt/vol) and
precipitating glycogen with ethanol
as described previously (20). The
radioactive glycogen was counted
and divided by the D-(3-3H)-glucose
specific activity to determine the
rate of synthesis.
Deoxyglucose uptake in isolated mus-
cles. Mice were anesthetized with
pentobarbital and soleus and
extensor digitorum longus muscles
were exposed. Ligatures were placed
around the tendon at each end of
the muscle. Muscles were suspend-
ed at resting tension (4–5 m New-
tons) and incubated at 30°C for 10
minutes at basal conditions in
incubation chambers (Multi myo-
graph system organ bath 700MO;
Danish Myo Technology A/S,
Aarhus, Denmark) oxygenated with
95% O2 and 5% CO2 gas. Basal
medium consisted of 0.01% BSA, 8 mM mannitol, and
2 mM pyruvate in Krebs-Henseleit buffer (118.5 mM
NaCl, 24.7 mM NaHCO3, 4.74 mM KCl, 1.18 mM
MgSO3, 1.18 KH2PO4, and 2.5 CaCl2, pH 7.4). After
basal incubation the medium was aspirated and
exchanged with medium containing 600 µU insulin/ml
(100 IU/ml Actrapid; Novo Nordisk A/S, Bagsvær, Den-
mark) for 30 minutes. 2-deoxy-D-glucose uptake meas-
urements were initiated by incubation in a medium
containing 600 µU insulin/ml, 1 mM 2-[2,6-3H]deoxy-
D-glucose with a specific activity in the medium of
0.128 mCi/ml, and 8 mM [1-14C]mannitol with a spe-
cific activity in the medium of 0.083 mCi/ml (Amer-
sham Biosciences Europe, Freiburg, Germany). Uptake
was measured for 10 minutes before the muscle was
washed in ice-cold Krebs-Henseleit buffer and quickly
frozen with aluminum tongs precooled in liquid nitro-
gen. Frozen muscles were digested in 250 µl 1 M NaOH
at 80°C for 10 minutes. The solution was neutralized
with 250 µl 1 M NaCl and spun at 13,000 g for 2 min-
utes. Radioactivity in the supernatant was measured
using liquid scintillation (Tri-Carb 2000; Packard
Instruments, Greve, Denmark).
Insulin release from isolated islets of Langerhans. The
insulin-secretory response of AMPKα2–/– β cells was
studied in collagenase-isolated islets of Langerhans.
After isolation, islets were cultured for 16 hours in
Ham’s F10 medium containing 10 mM glucose. Insulin
release was measured by perifusion experiments in a
multiple microchamber module (Endotronics Inc.,
Coon Rapids, Minnesota, USA) as previously described
(21). Approximately 200 islets were loaded onto Biogel
P2 (Biorads Labs, Richmond, California, USA) in a col-
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Figure 1
Generation of mice lacking AMPKα2. (a) Schematic representation (not to scale) of genom-
ic structure of AMPKα2 wild-type allele, AMPKα2 gene-targeting construct, AMPKα2 target-
ed allele, and AMPKα2 null allele. Squares indicate loxP sites and H’s indicate HindIII restric-
tion sites. C corresponds to the exon encoding the AMPKα2 catalytic domain (amino acids
189–260) (b) Southern blot analysis after HindIII digestion of tail DNA from offspring derived
from heterozygous intercrosses. Expected fragment sizes of the AMPKα2 wild-type (+/+; 
5.3 kb) and null (–/–; 3.8 kb) alleles after HindIII digestion and hybridization with the indi-
cated probe (solid bar in a) are shown. (c) Western blot analysis of AMPKα1 and AMPKα2
proteins in liver and gastrocnemius muscle from control (+/+) and AMPKα2–/– mice. (d) Phos-
phorylation level of ACC in liver and gastrocnemius muscle from control and AMPKα2–/– mice.
umn and preperifused for 20 minutes in Ham’s F10
medium supplemented with 0.5% (wt/vol) BSA, 2 mM
glutamine, 2 mM CaCl2, and 3 mM glucose, equilibrat-
ed with 95% O2 and 5% CO2. At a flow rate of 0.5
ml/min, 15-minute pulses of 3 mM glucose were alter-
nated with 10-minute pulses of 7.5 mM glucose, 10 mM
glucose, 20 mM glucose, and 10 mM glucose with 20
mM L-arginine (Sigma-Aldrich). Samples were collected
every minute and assayed for immunoreactive insulin
with guinea pig anti-insulin serum (Linco Research Inc.,
St. Charles, Missouri, USA). Results were expressed as
percentages of the insulin content measured in each
individual batch of islets after finishing the experiment
by sonicating the Biogel P2 containing the islets in 5 ml
of 2 mM acetic acid and 0.25% (wt/vol) BSA.
Western blot analysis. Liver AMPK was obtained by
polyethylene glycol precipitation (2), and muscle
AMPK was prepared as previously described (5). AMPK
catalytic subunits were detected using specific anti-
AMPKα1 and anti-AMPKα2 antibodies (kindly pro-
vided by G. Hardie, Dundee University, Dundee, Scot-
land, United Kingdom). The phosphorylation status of
acetyl-CoA carboxylase (ACC) was visualized using an
anti–phospho-ACC (serine 79) antibody (Upstate
Biotechnology Inc., Lake Placid, New York, USA).
Statistical analysis. Data are expressed as mean ± SEM.
Statistical analyses were carried
out using an unpaired, two-tailed
Student t test, and the null
hypothesis was rejected at 0.05.
Results
Animal model: AMPKα2–/– mice.
AMPKα2 gene knockout was
obtained using a targeting vector
inserting loxP sites flanking the
sequence containing the enzymat-
ic catalytic site (Figure 1a). Dele-
tion of the targeted allele was car-
ried out by mating to EIIa-Cre
transgenic mice to cause germline
excision (16). Mice harboring the
deleted allele were identified by
Southern blot analysis (Figure 1b). Using RT-PCR
analysis, no amplification of the region corresponding
to the catalytic domain of AMPKα2 was observed in
the liver, skeletal muscle, or pancreas of AMPKα2–/–
mice (data not shown). Western blot analysis of protein
extracts prepared from AMPKα2–/– liver and skeletal
muscle showed undetectable AMPKα2 protein (Figure
1c). The AMPKα1 protein level was similar in the liver
of AMPKα2–/– and control mice (Figure 1c). In contrast,
in AMPKα2–/– mice, AMPKα1 protein was increased
1.8-fold in gastrocnemius muscle (Figure 1c). Phos-
phorylation of ACC was decreased in gastrocnemius
muscle 3.5-fold, while it was unchanged in the liver
compared with controls (Figure 1d).
Physical appearance, body weight, body composition, and
triglyceride content in tissues of AMPKα2–/– mice.
AMPKα2–/– mice from heterozygous mating were born
with the expected mendelian ratio. AMPKα2–/– mice
are fertile, appear indistinguishable from their wild-
type littermates, and have a normal life span. No sig-
nificant difference in body weight or food intake was
observed between the two groups (Table 1). Body com-
position was similar for both groups as assessed both
by biphotonic absorptiometry (Table 1) and careful
dissection and weighing of individual organs (data not
shown). Triglyceride content in liver, gastrocnemius
muscle, and pancreas was similar in AMPKα2–/– mice
and controls (Table 1).
Metabolic parameters. In fasted conditions, plasma
glucose and insulin levels were similar in AMPKα2–/–
mice and controls, while plasma FFA concentrations
were increased in AMPKα2–/– mice (Table 2). Glycerol
plasma levels have a tendency to be higher in
AMPKα2–/– mice but do not reach statistical signifi-
cance (Table 2). In the fed state, AMPKα2–/– mice were
characterized by higher plasma glucose and plasma
FFA concentrations than were found in control mice,
while plasma insulin and leptin levels were lower
(Table 2). No difference between plasma levels of total
and HDL cholesterol, sodium, potassium, creatinine,
or urea were noted between AMPKα2–/– and control
mice (Table 2 and data not shown).
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Table1
Body composition, food intake, and triglyceride content of liver, gas-
trocnemius muscle, and pancreas of AMPKα2–/– mice
Control AMPKα2–/–
Body weight (g) 28.8 ± 0.9 29.6 ± 0.8
Fat-free mass (g)A 21.6 ± 0.6 21.7 ± 0.6
% fat massA 7.1 ± 0.3 6.7 ± 0.2
Food intake (g/d) 3.7 ± 0.1 3.8 ± 0.1
Liver TG content (mg/g tissue) 11.2 ± 0.7 14.0 ± 3.2
Muscle TG content (mg/g tissue) 11.7 ± 2.7 8.1 ± 0.9
Pancreas TG content (mg/g tissue) 6.1 ± 1.2 5.2 ± 0.6
ABody composition was assessed by biphotonic absorptiometry. All data are
expressed as mean ± SEM (n = 6–10 mice/group). P not significant between
groups by unpaired, two-tailed Student t test. TG, triglyceride.
Table 2
Metabolic parameters of AMPKα2–/– mice in fasted and fed periods
Fasted Fed
Control AMPKα2–/– Control AMPKα2–/–
Glycemia (mg/dl) 102 ± 5 101 ± 13 141 ± 10 171 ± 9B
Insulin (ng/ml) 0.46 ± 0.17 0.29 ± 0.08 1.35 ± 0.07 1.07 ± 0.12B
Leptin (ng/ml) 0.38 ± 0.10 0.38 ± 0.13 4.31 ± 0.24 2.65 ± 0.49A
FFA (mM) 1.10 ± 0.04 1.37 ± 0.06A 0.73 ± 0.06 0.95 ± 0.07B
Glycerol (µM) 367 ± 14 388 ± 15 281 ± 24 312 ± 31
TG (mM) 0.58 ± 0.02 0.74 ± 0.07 0.72 ± 0.05 0.91 ± 0.13
β-hydroxybutyrate (mM) 0.98 ± 0.09 1.17 ± 0.11 0.07 ± 0.01 0.08 ± 0.01
Total cholesterol (mM) 2.3 ± 0.2 2.9 ± 0.1 2.3 ± 0.2 2.6 ± 0.3
HDL cholesterol (mM) 1.7 ± 0.1 1.9 ± 0.2 1.5 ± 0.3 1.7 ± 0.2
All data are expressed as mean ± SEM (n = 6–10 mice/group). AP < 0.01, BP < 0.05 vs. control group by
unpaired, two-tailed Student t test.
AMPKα2–/– mice are AICAR-resistant, glucose intolerant,
and have reduced glucose-stimulated insulin secretion. To
investigate in vivo to what extent remaining AMPKα1
protein levels can substitute for AMPKα2, we per-
formed an AICAR tolerance test. The relative insensi-
tivity to hypoglycemia-mediated AICAR effects
observed in AMPKα2–/– mice (Figure 2a) suggests that
AMPKα1 cannot fully compensate for the lack of
AMPKα2 in AMPKα2–/– mice. To investigate the
dynamic response of AMPKα2–/– mice to increased glu-
cose concentrations, an oral glucose challenge was per-
formed. Following glucose absorption, AMPKα2–/–
mice have a markedly increased blood glucose excur-
sion, demonstrating glucose intolerance (Figure 2b).
Insulinemia determined at time 20 minutes was signif-
icantly lower in AMPKα2–/– mice (Figure 2c).
Glucose- and L-arginine–stimulated insulin secretion are nor-
mal in isolated pancreatic islets of AMPKα2–/– mice. No sig-
nificant difference in insulin release was observed
between control and AMPKα2–/– pancreatic islets for
basal (3 mM glucose) and stimulatory glucose concen-
trations (7.5 mM, 10 mM, and 20 mM glucose) or when
challenged with 20 mM L-arginine (Figure 3). Further-
more, the insulin content of AMPKα2–/– and control
islets was similar (67.2 ± 16.2 vs. 63.9 ± 16.5 ng/islet in
controls; P not significant).
AMPKα2–/– mice are insulin resistant while Tg-KD-
AMPKα2 mice are not. In the basal condition, endoge-
nous glucose production, glycolysis rate, and whole-
body glycogen synthesis rate were similar
between AMPKα2–/– and control mice (Table
3). In vivo muscle glycogen synthesis rate and
total glycogen content were similar in both
groups (Table 3). During hyperinsulinemic
euglycemic clamp, plasma glucose
and insulinemia were comparable
in AMPKα2–/– and control mice
(plasma glucose: 109.8 ± 7.2 mg/dl
in AMPKα2–/– mice vs. 97.2 ± 3.6
mg/dl in controls, P not significant;
plasma insulin: 159.7 ± 22.6 mU/l
in AMPKα2–/– mice vs. 146.9 ± 22.5
mU/l in controls, P not significant).
Insulin-stimulated whole-body glu-
cose turnover rate was decreased in
AMPKα2–/– mice compared with
controls (Table 3). Insulin-stimulat-
ed whole-body glycolysis was simi-
lar in both groups, while the
insulin-stimulated whole-body gly-
cogen synthesis rate was dramati-
cally decreased in AMPKα2–/– mice (Table 3). Muscle
glycogen synthesis rate and total muscle glycogen con-
tent were severely reduced in AMPKα2–/– mice com-
pared with controls at the end of the clamp (Table 3).
Because glucose uptake is largely rate limiting for
glycogen synthesis in muscle during clamp study, we
assayed uptake of deoxyglucose into isolated muscle
in the presence of insulin. Basal and insulin-stimulat-
ed glucose uptake were similar in isolated extensor dig-
itorum longus and soleus muscles from controls and
AMPKα2–/– mice (Figure 4, a and b). In addition, total
glycogen content in skeletal muscle of random-fed ani-
mals was similar between AMPKα2–/– and control mice
(0.312 ± 0.106 vs. 0.358 ± 0.072 µg/mg in controls,
respectively, P not significant). Lastly, endogenous
hepatic glucose production was totally inhibited in
both groups, suggesting no hepatic insulin resistance
(data not shown). Furthermore, no defect was detect-
ed in glycogen synthesis or total glycogen content in
the liver of AMPKα2–/– and control mice in either basal
or clamp studies (data not shown).
To further investigate the role of muscle AMPK in
the development of insulin resistance, we performed
hyperinsulinemic euglycemic clamps in transgenic
mice expressing a kinase-dead mutant of AMPK in
skeletal muscle (Tg-KD-AMPKα2 mice) and their
respective nontransgenic controls (17). Oral glucose
tolerance was comparable between the two groups
(data not shown). During the clamp, plasma glucose
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Figure 2
AMPKα2–/– mice are AICAR-resistant, glucose intolerant, and exhibit impaired glucose-stim-
ulated insulin secretion. (a) AICAR tolerance test. (b) OGTT. (c) Plasma glucose and insulin
levels at time 20 minutes during OGTT. All results are expressed as mean ± SEM (n = 6–10).
*P < 0.05, **P < 0.001, ***P < 0.0001 vs. control group by unpaired, two-tailed Student 
t test. NS, not significant. 
Figure 3
Glucose- and L-arginine–stimulated (L-Arg) insulin secre-
tion in isolated AMPKα2–/– islets. All results are expressed
as mean ± SEM (n = 4). P not significant between groups
by unpaired, two-tailed Student t test.
and insulinemia were comparable in Tg-KD-AMPKα2
and nontransgenic mice (plasma glucose: 93.6 ± 1.8
mg/dl in Tg-KD-AMPKα2 mice vs. 95.4 ± 9.0 mg/dl in
nontransgenic controls, P not significant; plasma
insulin: 113.7 ± 24.8 mU/l in Tg-KD-AMPKα2 mice vs.
145.7 ± 22.9 mU/l in nontransgenic controls, P not sig-
nificant). Insulin-stimulated whole-body glucose
turnover, whole-body glycogen synthesis rate, muscle
glycogen synthesis rate, and total muscle glycogen
content were similar in both groups (Table 3).
Increased daily urinary catecholamine excretion in
AMPKα2–/– mice. Daily epinephrine, norepinephrine,
and dopamine excretion were significantly higher in
AMPKα2–/– mice than in controls (Figure 5, a–c). The
response to a glucose challenge was dramatically
improved in AMPKα2–/– mice after treatment with 
α-adrenergic blockers, while no change was observed in
control mice (Figure 5, d and e). In contrast, β-adren-
ergic blockers did not modify glucose tolerance of
AMPKα2–/– mice (Figure 5, d and e).
Discussion
The primary goal of this study was to assess the role of
the AMPKα2 isoform in controlling glucose metabo-
lism in vivo. AMPKα2–/– mice appear indistinguishable
from their control littermates. Importantly, there is no
difference in body composition, adiposity, or food
intake between mutant and control mice. The most
striking observation is reduced glucose tolerance in
AMPKα2–/– mice. We showed that this defect is linked
with both reduced insulin release and decreased insulin
sensitivity of peripheral tissues. Few data are available
concerning regulation of insulin release by AMPK.
Activation of AMPK has been shown to inhibit insulin
secretion in vitro (9, 10). Here, we showed that while
glucose-induced insulin secretion is clearly impaired in
AMPKα2–/– mice in vivo, basal and glucose- and L-argi-
nine–stimulated insulin secretion in isolated pancreat-
ic islets are similar in AMPKα2–/– mice and controls.
Furthermore, insulin content of islets and insulin gene
transcription (data not shown) were not affected by
AMPKα2 gene deletion. Taken together, these data
indicate that the lack of insulin secretion observed in
vivo in AMPKα2–/– mice is not due to a primary defect
in β cell function. Hypokalemia or hyperleptinemia
(22), known to modulate insulin secretion negatively in
vivo, are not observed in AMPKα2–/– mice. In addition,
lipid content in pancreas was similar in AMPKα2–/–
mice and controls, excluding a deleterious effect on
insulin release by chronic accumulation of lipids (23,
24). An important regulator of insulin secretion is the
fine-tuning of the balance between sympathetic and
parasympathetic activity. This is critical for the β cells,
since epinephrine and norepinephrine directly and
potently suppress β cell function (25). AMPKα2–/– mice
exhibited higher catecholamine urinary excretion than
did controls. Since catecholamines are known to inhib-
it insulin release, dysregulation in sympathetic tone
observed in AMPKα2–/– mice could be implicated in the
reduction of insulin secretion. More importantly, no
defect in glucose and insulin plasma levels was
observed in mutant mice in the fasted state, suggesting
that dysregulation of sympathetic tone is predominant
in the fed period.
Glucose intolerance is due to both impaired insulin
secretion and reduced insulin-stimulated glucose uti-
lization. Therefore, we examined insulin sensitivity in
peripheral tissues of AMPKα2–/– mice using hyperinsu-
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Table 3
Metabolic parameters of AMPKα2–/– and Tg-KD-AMPKα2 mice during basal and hyperinsulinemic euglycemic clamp studies
Weight Whole-body Whole-body Whole-body glycogen Muscle glycogen Muscle glycogen 
glucose turnover glycolysis rate synthesis rate synthesis rate content
(g) (mg/kg/min) (mg/kg/min) (mg/kg/min) (ng/mg/min) (µg/mg)
Basal
Control 24.7 ± 1.2 24.2 ± 1.6 10.3 ± 0.5 13.9 ± 1.5 48.4 ± 14.6 0.035 ± 0.013
AMPKα2–/– 24.7 ± 1.0 25.6 ± 1.9 9.2 ± 0.7 16.4 ± 2.0 15.7 ± 4.1 0.020 ± 0.006
Clamp
Control 22.3 ± 0.5 90.6 ± 4.3 19.7 ± 2.9 71.0 ± 2.5 611.8 ± 143.2 0.458 ± 0.113
AMPKα2–/– 21.4 ± 0.5 68.7 ± 2.9A 21.8 ± 1.6 46.9 ± 2.9A 143.9 ± 17.0A 0.137± 0.030B
NTg 27.2 ± 0.5 64.2 ± 7.0 14.8 ± 1.0 45.9 ± 6.9 108.9 ± 50.9 0.175 ± 0.053
Tg-KD-AMPKα2 25.1 ± 1.3 72.9 ± 5.3 16.5 ± 3.6 56.4 ± 7.3 89.9 ± 21.0 0.172 ± 0.050
All data are expressed as mean ± SEM (n = 6–12 mice/group). AP < 0.01, BP < 0.05 vs. control group by unpaired, two-tailed Student t test. NTg, nontransgenic.
Figure 4
Insulin-stimulated glucose transport in isolated muscles from
AMPKα2–/– mice. Basal and insulin-stimulated glucose transport in (a)
soleus and (b) extensor digitorum longus muscles from control and
AMPKα2–/– mice. All results are expressed as mean ± SEM (n = 4–7).
*P < 0.05, **P < 0.01 vs. basal conditions by unpaired, two-tailed Stu-
dent t test; P not significant (NS) vs. control group.
linemic euglycemic clamp studies. To our surprise,
AMPKα2–/– mice displayed decreased whole-body
insulin sensitivity, with a dramatic reduction in
insulin-stimulated glycogen synthesis in skeletal mus-
cle, while hepatic insulin sensitivity was preserved.
Does α2 deletion in skeletal muscle directly alter
insulin sensitivity? This does not seem to be the case
since insulin sensitivity is unaltered in Tg-KD-
AMPKα2 mice, which express a dominant-negative
mutant of AMPK in skeletal muscle (17). This points
out that lack of AMPK activity in skeletal muscle is
unable by itself to alter insulin sensitivity or glycogen
synthesis in this tissue. Likewise, comparable muscle
glycogen contents of AMPKα2–/– and control mice dur-
ing the random-fed period suggest that the balance
between degradation and repletion of glycogen in mus-
cle is intact in this model. In consequence, a defect in
muscular glycogen synthesis was specifically observed
in AMPKα2–/– mice when insulinemia reached supra-
physiological levels. Glucose uptake is largely rate lim-
iting for glycogen synthesis in muscle during clamp
study. As insulin induced a similar increase in
deoxyglucose uptake in incubated extensor digitorum
longus and soleus muscles, it is unlikely that primary
defective glucose transport in muscle contributes to
AMPKα2–/– insulin resistance. 
Another known important mechanism of insulin
resistance in skeletal muscle is increased lipid availabili-
ty or increased tissue uptake of FFA (26). AMPK regu-
lates lipid oxidation in muscle by reducing ACC activity,
which in turn decreases malonyl coenzyme A levels and
increases mitochondrial uptake of FFAs. In AMPKα2–/–
gastrocnemius muscle, we showed that α1 protein was
increased by 1.8-fold (Figure 1c) but ACC phosphoryla-
tion was reduced by 3.5-fold (Figure 1d). These data sug-
gest that in skeletal muscle, the increased α1 protein lev-
els in AMPKα2–/– mice is not sufficient to ensure normal
phosphorylation of ACC. However, the 24-hour respira-
tory quotient, monitored by indirect calorimetry, was
similar in AMPKα2–/– and control mice (data not
shown), suggesting that whole-body lipid oxidation is
not altered by the lack of the AMPKα2 subunit. Fur-
thermore, comparable skeletal muscle lipid content in
both groups argues against any alteration of lipid oxi-
dation rate in AMPKα2–/– mice. Finally, we know that
adipose tissue operates as an endocrine organ that releas-
es a large number of hormones in response to specific
extracellular stimuli or changes in metabolic status.
Alteration of secretion of these proteins (which include
TNF-α, leptin, adipsin, resistin, and adiponectin) as a
possible mechanism of AMPKα2–/– mouse insulin resist-
ance needs further investigation.
So how can we explain insulin resistance in AMPKα2–/–
mice? The observation that AMPKα2–/– mice exhibit
altered glucose metabolism in vivo but not in isolated
organs suggests that the defect is of central origin. It is
known that integration of peripheral and central meta-
bolic signals in the CNS during different metabolic sit-
uations such as fasting, fed state, and hyperinsulinemic
clamp activates the autonomous nervous system, which
in turn regulates glucose metabolism in peripheral tis-
sues (27–30). As AMPKα2 is widely expressed in the
brain (13), we hypothesized that lack of AMPKα2 in neu-
rons could contribute to the metabolic defects observed
in AMPKα2–/– mice. Supporting this hypothesis,
AMPKα2–/– mice exhibited a significant increase in daily
urinary catecholamine excretion, suggesting higher sym-
pathetic activation in these mice. Furthermore, the glu-
cose intolerance of AMPKα2–/– mice was dramatically
improved after intraperitoneal injection of phento-
lamine (an α-adrenergic receptor antagonist), while no
change was observed after treatment of AMPKα2–/– mice
by propranolol (a β-adrenergic receptor antagonist). This
suggested that the α-adrenergic but not the β-adrener-
gic pathway is involved in the glucose intolerance
observed in AMPKα2–/– mice. It is well known that epi-
nephrine overproduction inhibits insulin secretion,
reduces insulin-stimulated glucose uptake in skeletal
muscles, and alters muscle glycogen synthesis (31–35);
all of these defects are present in AMPKα2–/– mice in vivo.
Moreover, normality of some metabolic parameters
(fasting glucose and insulin plasma levels or skeletal
muscle glycogen content in random-fed animals) sug-
gests that exaggerated sympathetic tone in AMPKα2–/–
mice is not permanent but is restricted to particular
nutritional situations such as glucose challenge and
hyperinsulinemic euglycemic clamps.
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Figure 5
Increased daily urinary catecholamine excretion in AMPKα2–/– mice.
Daily urinary (a) epinephrine, (b) norepinephrine, and (c) dopamine
excretion in AMPKα2–/– mice. All results are expressed as mean ±
SEM (n = 6). *P < 0.05, **P < 0.01 vs. control group by unpaired,
two-tailed t test. Also shown are effect of phentolamine and pro-
pranolol, α- and β-adrenergic blockers, respectively, on the response
of glucose challenge of control (d) and AMPKα2–/– (e) mice. All
results are expressed as mean ± SEM (n = 5). *P < 0.05, **P < 0.01,
saline- vs. phentolamine-treated group by unpaired, two-tailed Stu-
dent t test; P not significant for saline- vs. propranolol-treated group.
The data presented here identify AMPKα2 as a major
component in the control of insulin sensitivity and
insulin secretion in vivo. We clearly demonstrated that
the metabolic function of AMPKα2–/– isolated skeletal
muscle and pancreatic islets is normal, suggesting that
the origin of the defects observed in vivo is located out-
side these tissues. In addition, we showed significant
increased catecholamine excretion in AMPKα2–/– mice.
Thus, we hypothesize that lack of AMPKα2 in neurons
reduces the ability to integrate peripheral metabolic
signals into the brain and consequently alters the con-
trol of peripheral insulin sensitivity and insulin secre-
tion by increasing sympathetic nervous activity.
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